BeiGene/Novartis's Tislelizumab Faces US Delay Over China Inspection Challenges

No Timetable in Sight

 
• By Brian Yang

An inability to conduct manufacturing field inspections in China due to strict local COVID-19 policies is cited as the only reason for the delay for the anti-PD-1 drug, for which the timescale for resolution is currently unclear.

CHINA ZERO COVID DETERS FDA INSPECTIONS TO THE COUNTRY
BEIGENE/NOVARTIS PD-1 AGENT FACES FDA APPROVAL DELAY DUE TO CHINA'S 'COVID ZERO' POLICIES • Source: Shutterstock

More from US FDA

More from Agency Leadership